Muscle cells injections fall short in "encouraging" heart trial
This article was originally published in Clinica
A trial to investigate the merits of implanting muscle cells in the heart as a treatment for heart failure (HF) has missed its goal, but has, nonetheless, yielded encouraging safety and secondary outcomes.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.